Knowing you have an increased risk of a subsequent stroke can be scary. But, by working with your doctor to develop an appropriate treatment plan, you can help reduce your risk. For some, this treatment plan may include AGGRENOX.
AGGRENOX is a prescription medicine that's FDA approved to lower the risk of stroke in people who have had either a TIA (transient ischemic attack or "mini-stroke") or stroke due to a blood clot.
AGGRENOX works by making platelets in the blood less sticky. That means they're less likely to clump together and form blood clots that can block blood flow to the brain—the cause of 87% of strokes.
AGGRENOX is proven to be effective
By combining 2 antiplatelet agents—aspirin and extended-release dipyridamole—AGGRENOX works better than either medicine alone to reduce the risk of a subsequent stroke.
In a clinical study, AGGRENOX helped reduce the risk of stroke in patients who had a TIA or stroke due to a blood clot:
- Over 90% of patients on AGGRENOX remained stroke-free for 2 years (1493 patients out of a total of 1650).
- Patients taking AGGRENOX twice daily were 22% less likely to have a stroke than patients taking low-dose aspirin (25 mg twice daily) alone.
- AGGRENOX was twice as effective as low-dose aspirin (25 mg twice daily) at reducing the risk of a subsequent stroke when tested against a sugar pill.
Dr Pappas talks about your increased risk of a subsequent stroke—and what you can do about it.
Learn about AGGRENOX
Find out how many patients in a clinical study remained stroke-free over 2 years.learn more
Stroke and TIA Stories
Find out how others are reducing
their risk of a
The Taking Smart Steps™ program
Get free tips, tools, and information to help you stay on track with your treatment.Enroll Now
for your next
Create a personalized doctor discussion guide to capture your questions
Insights for caregivers
Caring for someone after a stroke can be difficult.Get info and advice that may help
Savings and support
Find out about savings on AGGRENOX and FREE support programs.learn more
Insight for caregivers
Get information tailored to those who are caring for someone who has experienced a stroke or TIA.learn more
Learn more about stroke and what you can do to reduce your risk with these resources.learn more
Door to Door Terms and Conditions
Patients must have a valid prescription for AGGRENOX.
By enrolling, I elect to receive the branded product and acknowledge that no generic substitution will be offered (if applicable). Should I wish to receive a generic product in the future, I will call 1-855-892-3438 to opt out of this program.
Patients without insurance restrictions and co-pays of $100 or less will pay a $0 co-pay for a one-month supply of AGGRENOX. For patients whose co-pay is between $100 and $135, they will pay that amount minus the maximum savings benefit of $100 per month. No one will pay more than $35. Patients with insurance restrictions or co-pays of more than $135, they will not be processed through insurance and will pay $35 for a one-month supply (60 capsules) of AGGRENOX.
If you have Medicare Part D, Medicaid or a similar state or federally funded medical assistance program, you will pay a cash price of $35 for a one-month supply of AGGRENOX. All Medicare Part D orders are processed without the use of insurance and cannot be applied to Part D true out of pocket (TrOOP) costs. Taxes may apply.
Boehringer Ingelheim Pharmaceuticals, Inc. retains the right to rescind, revoke, or amend this offer at any time without notice.